Additively Enhanced Antiproliferative Effect of Interferon Combined with Proanthocyanidin on Bladder Cancer Cells by Fishman, Andrew I. et al.
Journal of Cancer 2012, 3 
 
 
http://www.jcancer.org 
107 
J Jo ou ur rn na al l   o of f   C Ca an nc ce er r   
2012; 3: 107-112. doi: 10.7150/jca.4107 
Research Paper 
Additively Enhanced Antiproliferative Effect of Interferon Combined with 
Proanthocyanidin on Bladder Cancer Cells 
Andrew I. Fishman, Blake Johnson, Bobby Alexander, John Won, Muhammad Choudhury, and Sensuke 
Konno
 
Department of Urology, New York Medical College, Valhalla, New York, USA.  
 Corresponding author: Sensuke Konno, Ph.D., New York Medical College, Department of Urology, Munger pavilion 4th Floor, Valhalla, 
NY 10595, USA. Phone: 914-594-3745; Fax: 914-594-4428 E-mail: sensuke_konno@nymc.edu. 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2012.01.17; Accepted: 2012.01.29; Published: 2012.03.01 
Abstract 
Although interferon (IFN) has been often used as immunotherapy for bladder cancer, its ef-
ficacy is rather unsatisfactory, demanding further improvement. Combination therapy is one 
of viable options, and grape seed proanthocyanidin (GSP) could be such an agent to be used 
with IFN because it has been shown to have anticancer activity. We thus investigated whether 
combination of IFN and GSP might enhance the overall antiproliferative effect on bladder 
cancer cells in vitro. Human bladder cancer T24 cells were employed and treated with the 
varying concentrations of recombinant IFN-α2b (0-100,000 IU/ml), GSP (0-100 g/ml), or their 
combinations. IFN-α2b alone led to a ~50% growth reduction at 20,000 (20K) IU/ml, which 
further declined to ~67% at ≥50K IU/ml. Similarly, GSP alone induced a ~35% and ~100% 
growth reduction at 25 and ≥50 g/ml, respectively. When IFN-α2b and GSP were then 
combined, combination of 50K IU/ml IFN-α2b and 25 g/ml GSP resulted in a drastic >95% 
growth reduction. Cell cycle analysis indicated that such an enhanced growth inhibition was 
accompanied by a G1 cell cycle arrest. This was further confirmed by Western blot analysis 
revealing that expressions of G1-specific cell cycle regulators (CDK2, CDK4, cyclin E and 
p27/Kip1) were distinctly modulated with such IFN-α2b/GSP treatment. Therefore, these 
findings support the notion that combination of IFN-α2b and GSP is capable of additively 
enhancing antiproliferative effect on T24 cells with a G1 cell cycle arrest, implying an adjuvant 
therapeutic modality for superficial bladder cancer. 
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Introduction 
Bladder cancer is the second most common uro-
logic malignancy next to prostate cancer in the United 
States, and the majority of bladder cancers present as 
superficial  (80%)  with  15%  presenting  as  invasive 
cancer  and  5%  as  metastatic  disease  (1).  Currently, 
transitional cell carcinoma (TCC) is the most preva-
lent primary bladder tumor: 50,000 new cases are di-
agnosed annually and over 10,000 people die of this 
disease  each  year  (2).  Although  endoscopic  tran-
surethral  resection  (TUR)  is  often  performed  as  a 
primary therapy, 50%-75% of patients will yet recur in 
5 years and about 10% progress to invasive disease 
(2). 
Chemotherapy is another viable option but in-
travesical administration of bacillus Calmette-Guerin 
(BCG), an attenuated strain of Mycobacterium bovis, is 
currently  the  most  effective  immunotherapy  for 
high-grade  and  recurrent  superficial  bladder  cancer 
and carcinoma in situ (CIS) (3). In randomized studies, 
BCG has been shown to be superior to both mitomy-
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cin C and adriamycin (4). Intravesical BCG following 
TUR has also been associated with a significant im-
provement in progression and survival compared to 
TUR alone (5). In fact, this protocol has become estab-
lished therapy for superficial bladder cancers, result-
ing  in  a  ~40%  reduction  in  cancer  recurrence  (6). 
However,  side  effects  of  BCG  therapy  are  common 
and limit its use in clinical practice, demanding a saf-
er,  more  effective  therapeutic  modality  with  fewer 
side effects. 
Interferons (IFNs) have been often used as im-
munotherapy for a variety of urologic malignancies 
including prostate, bladder, and renal cell carcinomas 
(7-9). Especially, IFN-α is used as an intravesical agent 
for treating superficial bladder cancer because it may 
cause  only  minor  local  and  systemic  toxicity  (com-
pared to BCG) (10). However, since its response rate 
in patients has been shown to be lower than that of 
BCG  therapy  (10),  the  efficacy  of  IFN-α  combined 
with  BCG  was  assessed  in  pilot  clinical  trials  and 
animal studies (11,12), indicating the better, improved 
outcomes.  Thus,  these  studies  would  certainly  en-
courage further exploration into other alternative com-
bination therapies, which may lead to the safer, more 
effective and satisfactory results. 
Proanthocyanidins are naturally occurring plant 
polyphenolic bioflavonoids in fruits, vegetables, nuts, 
seeds, flowers and bark (13). They are known as nat-
ural antioxidants, having biological, pharmacological 
and  chemoprotective  properties  against  oxidative 
stress or harmful free radicals (13-15). For example, 
hydrogen peroxide-induced oxidative stress was sig-
nificantly reduced by proanthocyanidins in cultured 
macrophage  and  neuroactive  PC-12  cells  (14).  They 
have  exhibited  antibacterial,  antiviral,  an-
ti-inflammatory, and vasodilatory actions as well (13). 
Particularly,  a  unique  grape  seed  proanthocyanidin 
(GSP)  has  been  extensively  characterized:  it  is  a 
standardized  water-ethanol  extract  from  red  grape 
seeds, consisting of oligomeric proanthocyanidins as 
active components (15). GSP has also demonstrated its 
anticancer (cytotoxic) effect on several malignancies 
including breast, lung and gastric cancers in vitro (16). 
Accordingly,  we  investigated  whether  IFN-α, 
GSP or their combination might demonstrate the an-
tiproliferative effect on bladder cancer cells  in vitro. 
We also explored the underlying mechanism – how 
the cancer cell growth might be inhibited with such 
agents,  focusing  on  the  cell  cycle  regulation.  More 
detailed studies are described and discussed herein. 
Materials and Methods 
Cell culture  
The  human  bladder  cancer  T24  cells,  derived 
from  a  patient  with  TCC,  were  obtained  from  the 
American  Type  Culture  Collection  (Manassas,  VA). 
Cells were cultured in McCoy’s 5a medium contain-
ing 10% fetal bovine serum, penicillin (100 U/ml), and 
streptomycin (100 g/ml), and were maintained at 37 
C in a humidified incubator in an atmosphere of 95% 
air and 5% CO2. For experiments, cells were seeded in 
6-well plates (2 ml per well) or T-75 flasks (10 ml per 
flask) at the initial cell density of 2 x 105 cells/ml and 
were  cultured  with  recombinant  interferon-α2b 
(IFN-α2b; Schering Corp., Kenilworth, NJ), grape seed 
proanthocyanidin  (GSP;  Dry  Creek  Nutrition,  Inc., 
Modesto,  CA)  or  their  combinations.  Cell  num-
ber/viability  was  then  assessed  at  specified  times 
using the trypan blue exclusion method.  
Cell cycle analysis  
A  FACScan  flow  cytometer  (Becton-Dickinson, 
San Jose, CA), equipped with a double discrimination 
module, was employed for cell cycle analysis. Control 
or agents-treated cells (~1 x 106 cells per condition) 
were first resuspended in 500 l of propidium iodide 
solution  (20  g/ml  propidium  iodide,  0.2  mg/ml 
RNase,  0.2  mg/ml  EDTA,  0.5%  Nonidet  P-40)  and 
incubated for 1 h at room temperature in the dark. 
Following incubation, ~10,000 nuclei from each sam-
ple were analyzed on a flow cytometer, and CellFit 
software  was  used  to  quantify  cell  cycle  compart-
ments to estimate the % of cells distributed in the dif-
ferent cell cycle phases.  
Western blot analysis  
The procedure essentially followed the protocol 
described previously (17). Briefly, an equal amount of 
proteins  (7  g)  from  control  and  agent-treated  cell 
lysates was resolved by 10% SDS-polyacrylamide gel 
electrophoresis  and  transferred  to  a  nitrocellulose 
membrane. The blot  was first incubated for 90 min 
with  the  primary  antibodies  against  CDK2,  CDK4, 
cyclin D1, cyclin E, or p27/Kip1 (Santa Cruz Biotech-
nology, Santa Cruz, CA), followed by incubation with 
the  secondary  antibody  conjugated  with  peroxidase 
for 30 min. The immunoreactive protein bands were 
detected by chemiluminescence following the manu-
facturer’s protocol (Kirkegaard and Perry Laborato-
ries, Gaithersburg, MD) and quantified using a scan 
densitometer (Silk Scientific, Oregon, UT). 
Statistical analysis  
All  data  were  presented  as  the  mean  ±  SD 
(standard  deviation),  and  statistical  differences  be-
tween groups were assessed with either the unpaired 
Student’s  t  test  or  one-way  analysis  of  variance 
(ANOVA). Values of p<0.05 were considered to indi- Journal of Cancer 2012, 3 
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cate statistical significance. 
Results 
Effects of interferon-2b and proanthocyanidin 
on T24 cell growth  
To  examine  possible  effects  of  interferon-α2b 
(IFN-α2b) and grape seed proanthocyanidin (GSP) on 
T24 cell growth, cells were cultured with the varying 
concentrations of IFN-α2b (0-100,000 = 100K IU/ml) or 
GSP (0-100 g/ml) for 72 h. IFN-α2b caused a signifi-
cant (~50%) growth reduction at 20K IU/ml, which 
further  declined  to  >67%  at  ≥50K  IU/ml  (Fig.  1A). 
Similarly, a ~35% and >90% growth inhibition were 
attained with 25 and ≥50 g/ml of GSP, respectively 
(Fig. 1B). A drastic growth reduction (~90%) with 50 
g/ml GSP was actually due to a cytotoxic effect, evi-
denced by ~30% of cells having been dead. These re-
sults thus show that IFN-α2b and GSP are capable of 
inhibiting T24 cell growth but GSP can also induce 
cytotoxic cell death at the higher (≥50 g/ml) concen-
trations. 
 
 
Fig. 1. Effects of IFN-α2b or GSP on T24 cell growth. Cells were 
cultured  with  the  varying  concentrations  of  either  IFN-α2b 
(0-100,000  IU/ml)  or  GSP  (0-100  g/ml),  and  cell  numbers  in 
IFN-α2b-treated (A) or GSP-treated (B) cells were determined at 
72 h. All data represent mean  SD (standard deviation) from 
three independent experiments (*p<0.05; **p<0.01). 
 
Additive antiproliferative effects of IFN-2b 
and GSP  
It  was  tempting  to  examine  whether  combina-
tions of IFN-α2b and GSP might improve the antipro-
liferative  effects.  As  25  g/ml  of  GSP  appeared  to 
induce a moderate (~35%) growth inhibition (Fig. 1B), 
this concentration was used in combination with the 
varying  concentrations  of  IFN-α2b.  Such  studies 
showed  that  combinations  of  GSP  (25  g/ml)  and 
IFN-α2b at 10K IU/ml (little effect by itself), 20K IU/ml 
(a  ~50%  inhibitory  effect),  and  50K  IU/ml  (a  ~67% 
inhibitory effect) led to the improved 43%, 79%, and 
>95% growth reduction (p<0.05), respectively (Fig. 2). 
Thus,  the  IFN-α2b/GSP  combinations  appear  to  in-
duce the additive antiproliferative effects on T24 cells. 
 
 
 
Fig. 2. Effects of combination of IFN-α2b and GSP on cell growth. 
Cells were treated with combinations of GSP (25 g/ml) and 10K, 
20K, or 50K IU/ml of IFN-α2b for 72 h, and cell growth was as-
sessed by the % of viable cell numbers relative to that in control 
(100%). The data are mean  SD from three separate experiments 
(*p<0.05; **p<0.03). 
 
Effects of IFN-2b and GSP on cell cycle  
To explore the mechanism of such additive ef-
fects  of  the  IFN-α2b/GSP  combinations,  cell  cycle 
analysis was performed using the specific concentra-
tions of IFN-α2b (20K IU/ml) and GSP (25 g/ml), which 
seemed to be rather suitable for this study. After T24 
cells were treated with IFN-α2b (20K IU/ml), GSP (25  Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
110 
g/ml), or their combination for 72 h, the results of 
cell cycle analysis were then summarized in Table 1. 
Compare to cell numbers of the G1 and S phases in 
controls,  significant  changes  in  those  numbers 
(p<0.05) were seen with IFN-α2b treatment, while GSP 
alone showed only the marginal effects. In contrast, 
the IFN-α2b/GSP combination induced a 58% increase 
and  64%  decrease  in  G1  and  S  phase  cell  numbers 
(p<0.05), respectively. This cell accumulation in the G1 
phase is known as a G1 cell cycle arrest (18). Thus, the 
IFN-α2b/GSP  combination  may  primarily  target  the 
G1-S phase transition in the cell cycle, subsequently 
leading to the growth cessation.  
 
Table 1 Effects of IFN-2b and GSP on Cell Cycle Phase 
Distributions. 
 Conditions  % of Cells in Cell Cycle Phases 
G1  S  G2/M 
 
Control 
 
49.3 ± 4.7 
 
 38.1 ± 2.8 
 
 12.6 ± 1.4 
 
+ IFN-2b (20K 
IU/ml) 
 
 61.7 ± 4.6* 
 
 26.7 ± 3.1* 
 
 11.6 ± 1.1 
 
+ GSP (25 g/ml) 
 
56.7 ± 5.0 
 
 33.2 ± 2.9 
 
 10.1 ± 1.6 
 
+ IFN-2b 
(20K)/GSP (25) 
 
 77.9 ± 4.3* 
 
 13.6 ± 1.4* 
 
 8.5 ± 0.9   
All data are mean ± SD from three separate experiments. 
* p<0.05 (compared to those in Control). 
 
 
Down-regulation of G1 cell cycle regulators by 
IFN-2b/GSP combination  
To confirm such an IFN-α2b/GSP-induced G1 cell 
cycle arrest, we also examined its effects on the spe-
cific cell cycle regulators for the G1-S phase transition 
(18).  After  cells  were  treated  with  or  without  the 
IFN-α2b (20K IU/ml)/GSP (25 g/ml) combination for 
72 h, the expressions of CDK2, CDK4, cyclin D1, cyclin 
E,  and  p27/Kip1  were  analyzed  on  Western  blots. 
Such analysis revealed that the expressions of CDK2, 
CDK4 and cyclin E were drastically reduced by ~80% 
with the IFN-α2b/GSP treatment (compared to those 
in controls), although no change in cyclin D1 was ob-
served (Fig. 3). In contrast, p27/Kip1 protein, a CDK2 
inhibitor, was significantly (~2.7 fold) up-regulated in 
IFN-α2b/GSP-treated  cells  (Fig.  3).  Thus,  altered  ex-
pressions of these regulators would provide the fur-
ther evidence for a blockage of G1-S phase transition, 
confirming  that  the  IFN-α2b/GSP-induced  growth 
inhibition is indeed mediated through a G1 cell cycle 
arrest. 
 
Fig. 3. Western blot analysis on cell cycle regulators. After cells 
were treated with or without the combination of IFN-α2b (20K 
IU/ml) and GSP (25 g/ml) for 72 h, the expressions of several cell 
cycle  regulators  were  analyzed  on  Western  blots.  Autoradio-
graphs  of  CDK2,  CDK4,  cyclin  D1,  cyclin  E,  and  p27/Kip1  in 
control and IFN-α2b/GSP-treated cells are shown for comparison. 
 
 
Effects of IFN-2b/GSP combination on prolif-
eration of other cancer cells 
Now,  one  may  raise  the  question  if  the 
IFN-α2b/GSP combination would also demonstrate its 
enhanced  antiproliferative  effect  on  other  bladder 
cancer  cells  or  different  cancer  cell  types.  This  was 
tested using another bladder cancer 5637 cells, pros-
tate cancer PC-3 cells, and renal cancer ACHN cells, 
which  had  been  treated  with  IFN-α2b  (20K  IU/ml), 
GSP (25 g/ml), or their combination for 72 h. Figure 
4 shows the effects of these agents on proliferation of 
three cancer cell lines. Overall, all cancer cells treated 
with  various  agents  exhibited  altered  growth  pat-
terns,  which  were  significantly  different  from  their 
respective  control  cells  (p<0.05).  IFN-α2b  alone  was 
capable of inducing a ~50% growth inhibition in both 
PC-3 and ACHN cells but a ~30% inhibition in 5637 
cells. GSP alone caused a lesser but 22-37% growth 
reduction  in  all  these  cells.  Nevertheless,  the 
IFN-α2b/GSP  combination  resulted  in  an  enhanced 
70%, 71%, and 68% growth inhibition in 5637, PC-3, 
and  ACHN  cells,  respectively.  Thus,  these  results 
suggest  that  the  IFN-α2b/GSP  combination  may 
commonly  demonstrate  its  potentiated  antiprolifera- Journal of Cancer 2012, 3 
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tive effect on not only T24 cells but also a variety of 
human cancer cells.  
 
 
Fig. 4. Growth inhibitory effect of IFN-α2b/GSP combination on 
various cancer cells. Bladder cancer 5637, prostate cancer PC-3, 
and renal cancer ACHN cells were treated with IFN-α2b (20K 
IU/ml), GSP (25 g/ml), or their combination for 72 h, and cell 
growth  was  assessed by  the %  of  viable  cell  number  (in  each 
condition) relative to that in respective control cells. The growth 
profile of T24 cells is also shown for comparison. All data are mean 
 SD from three separate experiments, showing statistically sig-
nificant  differences  (p<0.05)  compared  to  respective  controls 
(100%). 
 
Discussion 
Although IFN-α has been often used as immu-
notherapy for bladder cancer because of its relatively 
low toxicity (compared to BCG), its less efficacy has 
been  also  inquired  for  a  significant  improvement. 
Additionally, IFN-α therapy has several drawbacks, 
such  as  high  cost  and  repeated  administration.  A 
standard intravesical IFN-α instillation is often carried 
out with 50-100 million IU of IFN-α (19), but whether 
this high dosage would be sufficient to induce optimal 
immunity is uncertain because of its short retention 
time inside the bladder (19). Accordingly, to improve 
the efficacy of such IFN-α monotherapy, clinical trials 
of combination therapy using IFN-α and BCG (11) have 
been conducted on patients with bladder cancer. De-
spite some encouraging outcomes, further studies are 
yet required for establishing the more potent, safer, 
and cost-effective treatment modalities. 
This interesting issue prompted us to explore an 
alternative approach using grape seed proanthocya-
nidin  (GSP)  in  combination  with  IFN-α2b,  because 
GSP has been shown to be a natural, non-toxic anti-
oxidant  with  anticancer  effect  (15,16).  Our  study 
showed that IFN-α2b or GSP was capable of individu-
ally  inducing  a  significant  growth  reduction  in  T24 
cells.  Interestingly,  GSP  also  exhibited  the  cytotoxic 
effect (inducing cell death) at its higher concentrations 
(≥50 g/ml). When combinations of IFN-α2b and GSP 
were tested to further improve the overall efficacy, all 
combinations resulted in the additively enhanced an-
tiproliferative effect, implying that both IFN-α2b and 
GSP  may  share  the  common  growth  regulatory 
pathway.  In  addition,  this  IFN-α2b/GSP-enhanced 
growth inhibition in T24 cells was also demonstrated 
in  another  bladder  cancer  (5637),  prostate  cancer 
(PC-3), and renal cancer (ACHN) cells (Fig. 4), sug-
gesting its prevalent potency over bladder cancer as 
well as various cancer cells. 
Our next aim was to probe the antiproliferative 
mechanism of IFN-α2b/GSP combination, focusing on 
the cell cycle regulation. Such study revealed that the 
IFN-α2b/GSP-induced  growth  inhibition  was associ-
ated with a 64% reduction in the S-phase cell popula-
tion, due to a blockage of the cells entering from the 
G1 to the subsequent S phase (i.e. a G1 cell cycle ar-
rest).  This  finding  was  also  verified  by  analyzing 
G1-specific cell cycle regulators: expressions of CDK2, 
CDK4,  and  cyclin  E  were  drastically  (~80%) 
down-regulated  while  p27/Kip1  was  greatly  (~2.7 
fold) up-regulated in IFN-α2b/GSP-treated cells. Spe-
cific modulations of these regulators are indicative of 
a G1 cell cycle arrest, which is the crucial cellular event 
leading ultimately to a growth cessation. Yet, it is also 
important  to  examine  the  IFN-mediated  signaling 
pathways  to  further  define  the  mechanism  of 
IFN-α2b/GSP-induced  growth  inhibition,  since  acti-
vation  of  specific  IFN-inducible  genes  by  signal 
transduction (20) is well known to dictate biological 
actions  of  IFNs  (including  IFN-α2b).  Such  study  is 
currently underway in our laboratory. 
It would be worthwhile mentioning the possible 
clinical  relevance  of  IFN-α2b/GSP-enhanced  antipro-
liferative effect. As a high-dose instillation of IFN-α 
leads to its high cost (19), it would be more practical if 
such  a  high  dosage  could  be  somehow  reduced 
without losing, or rather, with improving its efficacy. 
Our study then showed that the relatively  low con-
centrations of IFN-α2b (compared to its monotherapy) 
were required to be highly effective when combined 
with  GSP.  This  suggests  that  the  combination  of  Journal of Cancer 2012, 3 
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IFN-α2b and GSP may not only help enhance IFN-2b 
activity but also help cut its cost down. However, it is 
yet required to address how the effective concentra-
tions (e.g., 20K or 50K IU/ml) of IFN-α2b and GSP in 
this in vitro study would be extrapolated to animals or 
actual  patients.  Nevertheless,  several  studies  have 
already reported antitumor activity of GSP in vivo. For 
example,  GSP  was  found  to  inhibit  prostate  tumor 
growth and angiogenesis (21) as well as breast cancer 
metastasis in mice (22) or enhance cytotoxic effect of 
doxorubicin  in  mice  bearing  Sarcorma  180 and  He-
patoma 22 (23). No palpable side effects of GSP have 
been  yet  reported  in  these  animal  studies,  and  the 
LD50 of GSP in the rats has been estimated to be >5,000 
mg/kg  body  weight  (24), verifying  its  low  toxicity. 
Moreover, patients with chronic pancreatitis demon-
strated the symptomatic improvements, such as the 
reduction in both pain index and incidence of vomit-
ing (25), with a daily dose of 200-300 mg of GSP. This 
also implies that GSP may have few side effects and is 
safe to be used in clinical practice. 
In conclusion, IFN-α2b and GSP can individually 
demonstrate antiproliferative effect on bladder cancer 
T24 cells. When they were combined, such inhibitory 
activity would be additively enhanced, resulting in a 
nearly  complete  growth  cessation.  In  addition,  this 
additive potentiation can be seen in other cancer cell 
types  as  well.  The  underlying  mechanism  of 
IFN-α2b/GSP-enhanced  growth  inhibition  appears  to 
be  more  likely  attributed  to  a  G1  cell  cycle  arrest. 
Therefore,  specific  IFN-α2b/GSP  combination  may 
provide alternative, adjuvant intravesical therapy for 
superficial bladder cancer. 
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